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AbSTrACT
Objectives Here, we present the reported incidence 
rates of inflammatory bowel disease (iBD) in patients 
receiving treatment with secukinumab for psoriasis (PsO), 
psoriatic arthritis (Psa) or ankylosing spondylitis (as), in 
a pooled analysis of 21 clinical trials.
Methods Data from all patients who had received at 
least one dose of secukinumab were included. safety 
analyses were conducted to evaluate cumulative iBD 
rates as well as per-year rates, by indication. Crohn’s 
disease (CD), ulcerative colitis (UC) and iBD unclassified 
(iBDU) events were analysed using exposure-adjusted 
incidence rates (patient incidence rates per 100 patient-
years (PY)).
results a total of 7355 patients with a cumulative 
exposure of 16 226.9 PY were included in the pooled 
analysis. among 5181 patients with PsO, there were 
14 cases of UC, 5 cases of CD and 1 case of iBDU, with 
exposure adjusted incidence rates (eaiRs) of 0.13, 0.05 
and 0.01, respectively. Of these 20 cases, 14 were new-
onset. in 1380 patients with Psa, there were 3 cases 
of UC, 3 cases of CD and 2 cases of iBDU (eaiRs 0.08, 
0.08 and 0.05); 7 of these represented new-onset cases. 
among 794 patients with as, there were 4 cases of UC, 
8 cases of CD and 1 case of iBDU (eaiRs 0.2, 0.4 and 
0.1); 9 were new-onset cases. in the per year analysis, 
the eaiRs for each indication did not increase over time 
with secukinumab treatment.
Conclusions in this pooled secukinumab safety analysis 
of 7355 patients across 21 clinical trials, cases of iBD 
events (including CD, UC and iBDU) were uncommon.
InTrOduCTIOn
Psoriasis (PsO), psoriatic arthritis (PsA) and anky-
losing spondylitis (AS) are chronic immune-me-
diated inflammatory diseases (IMID) that show 
significant coheritability with inflammatory bowel 
disease (IBD). Patients with PsO, PsA and AS have 
a 1–4-fold increased risk,1–6 relative to the back-
ground population, of developing IBD (see online 
supplementary table S1). IBD comprises two prin-
ciple phenotypes, Crohn’s disease (CD) and ulcer-
ative colitis (UC). CD and UC are chronic disorders 
characterised by intermittent phases of remission 
and relapse of active inflammation7 and have symp-
toms including abdominal pain, diarrhoea and rectal 
bleeding. The risk architecture of PsO, PsA, AS and 
IBD is polygenic and often overlapping,8–11 which 
may explain aggregation of IMID with multiple 
phenotypes across different generations. Moreover, 
one half of all patients with spondyloarthritis have 
documented microscopic intestinal inflammation,12 
and of these, approximately 7% develop IBD that 
satisfy accepted diagnostic criteria.13
Key messages
What is already known about this subject?
 ► Secukinumab is a fully human monoclonal 
antibody that inhibits interleukin (IL)-17A and 
has shown significant efficacy in the treatment 
of psoriasis (PsO), psoriatic arthritis (PsA) and 
ankylosing spondylitis (AS).
 ► There is evolving evidence regarding the 
association of inflammatory bowel disease (IBD) 
(ulcerative colitis and Crohn’s disease) and IL-
17A inhibition.
What does this study add?
 ► This manuscript includes data from a 
large safety analysis (n=7355; cumulative 
exposure=16 2260.9) across 21 clinical trials, 
spanning up to 5 years of treatment for PsO 
and PsA and up to 4 years in AS. Additionally, 
available postmarketing safety surveillance data 
are also included.
 ► IBD events were uncommon with secukinumab 
treatment and the observed exposure adjusted 
incidence rates of IBD did not increase over 
time.
How might this impact on clinical practice or 
future developments?
 ► This manuscript adds clinically meaningful 
evidence regarding the observed incidence rates 
of IBD in patients with PsO, PsA and AS treated 
with secukinumab.
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Dysregulation of mucosal cytokines, including interleukins 
(IL)-1 and IL-12, and tumour necrosis factor alpha (TNF),14 
promotes IBD pathogenesis. TNF antagonist therapy is effective 
and widely used for management of active CD and UC. Recently, 
IL-23 has been implicated in murine chronic intestinal inflam-
mation; genome-wide association studies of patients with CD 
suggest a central role for IL-23 gene variants in human disease.15 
Blockade of IL-12/IL-23 or IL-23 alone can improve CD.16–18 
Discrete from IL-12/IL-23 biology, several murine studies impli-
cate IL-17A in gastrointestinal homeostasis and tissue repair, 
rather than driving pathogenic inflammation as it does in PsO.19 
Thus, contrasting data inform the roles of IL-23 and IL-17A 
in gastrointestinal health and disease. In theory, inhibition of 
IL-17A may have dual effects, reducing inflammation, but also 
potentially impairing residual function of an already damaged 
epithelial barrier.20 21
Secukinumab, a fully human monoclonal antibody that 
inhibits IL-17A, has shown significant efficacy in the treatment 
of PsO, PsA and AS demonstrating rapid onset of action.22–27 
Detection of IBD has been reported in patients being treated 
with IL-17 inhibition.28–30 Herein, we comprehensively evalu-
ated the observed incidence rates of IBD in patients receiving 
treatment with secukinumab for a primary indication of PsO, 
PsA or AS. Specifically, we report the incidence of CD, UC and 
IBD-unclassified (IBDU) from a pooled database of 21 phase III/
IV clinical trials of secukinumab across the three indications and 
also review the postmarketing data from secukinumab periodic 
safety reports.
MeTHOdS
Analysis design and integrated data
Data were pooled from 21 randomised controlled clinical trials 
of secukinumab in PsO (14 phase III trials and 1 phase IV trial), 
PsA (3 phase III trials) and AS (3 phase III trials) indications (see 
online supplementary table S2 for details). An analysis of the 
entire secukinumab treatment period was performed on safety 
data pooled at the patient level from commencement date up to 
25 June 2017 (cut-off date of the latest periodic safety update 
report (PSUR)). Data from all patients who had received at least 
one dose of secukinumab (including non-responder placebo 
patients who, as per study protocol, were re-randomised to 
secukinumab treatment at the end of the placebo-controlled 
observation period) were included; this safety dataset is larger 
than the dataset used for typical efficacy analyses and thus incor-
porates a larger representative sample size. A separate safety 
analysis of short-term treatment (12–16 weeks) from the place-
bo-controlled phase of trials was also conducted. Similar to the 
entire treatment period analysis, data from all patients who 
had received at least one dose of secukinumab were included. 
Additionally, an analysis for risk difference meta-analysis was 
undertaken on the short-term (up to 12 and up to 16 weeks), 
placebo-controlled phase data for phase III trials (4 PsO trials 
(FIXTURE, ERASURE, FEATURE and JUNCTURE), 5 PsA 
trials (FUTURE1-FUTURE5) and 4 AS trials (MEASURE1-MEA-
SURE4)). Finally, postmarketing data are reported from the peri-
odic safety surveillance for secukinumab across the PSO, PsA and 
AS indications from December 2014 to June 2017.
Patients
A history of IBD was not an exclusion criterion in the secuk-
inumab PsO, PsA and AS studies. However, patients were 
excluded from the AS studies if they had active IBD or from the 
PsO and PsA studies if they had active ongoing inflammatory 
diseases other than PsO/PsA that might confound the evaluation 
of therapy. Patients who received placebo, and who did not meet 
prespecified response criteria, were switched to secukinumab 
at the end of the placebo-controlled observation period (Weeks 
12–24). Physician-reported IBD included cases of CD, UC and 
IBDU (all IBD related assessments were based on each physi-
cian’s clinical judgement, and no specific diagnostic procedures 
or criteria were mandated). Patients were questioned regarding 
adverse events (AEs) at each study visit, or AEs were volunteered 
by the patient during or between visits or through physical 
examination, laboratory tests or other assessments.
data analysis
Safety analyses were conducted to evaluate cumulative safety by 
indication as well as per-year safety by indication (Baseline to 
Year 1, Year 1 to Year 2 and so on). CD, UC and IBDU rates 
were analysed using exposure-adjusted incidence rates (patient 
incidence rates per 100 patient-years (PY)) over the entire 
secukinumab treatment period and for the postmarketing data 
analysis, while crude rates (n, %) were used in the short-term 
(placebo-controlled phase) analysis. All licensed and unlicensed 
(eg, 75 mg) doses of secukinumab were included in the analyses.
The Medical Dictionary for Regulatory Activities (MedDRA) 
V.20.0 was used to analyse AEs. A search was conducted for 
the reporting interval in the Novartis Safety Database (Argus). 
The following search criterion was used to retrieve cases: ‘IBD’ 
(narrow Novartis MedDRA query) as the high level term (or 
level 1 term), which includes ‘Crohn’s disease’ and ‘colitis ulcer-
ative’ and ‘inflammatory bowel disease’ as preferred terms (PTs) 
(or level 2 terms).
Exacerbations were defined as IBD events occurring in patients 
with a stated history of the disease at baseline. A history of IBD 
was physician-assessed based on patient history at baseline. 
New-onset cases of IBD were IBD events occurring in patients 
with no prior history of IBD at baseline.
In the risk difference meta-analysis, the following specific PTs 
were considered separately as risks: ‘Crohn’s disease’ for CD 
and ‘colitis ulcerative’ or ‘colitis’ for UC. The Mantel-Haenszel 
method of Greenland and Robins31 was used to estimate the abso-
lute rate difference for all studies combined, assuming a fixed 
effect model. The results of each meta-analysis are presented as 
a forest plot (see online supplementary figure S1).
reSulTS
The analysis included a total of 7355 patients with a cumulative 
secukinumab exposure of 16 226.9 PY pooled from 21 clinical 
trials and included data for up to 5 years for PsO and PsA and 
up to 4 years in AS. This included 5181 patients with PsO with 
a cumulative exposure of 10 416.9 PY, 1380 patients with PsA 
with a cumulative exposure of 3866.9 PY and 794 patients with 
AS with a cumulative exposure of 1943.1 PY.
baseline characteristics
Baseline characteristics are shown in table 1; approximately 
two-third of the PsO/AS cohort and approximately half of the 
PsA cohort were male with mean age ranging between 42 and 
49 years. Each cohort included a sizeable proportion of patients 
who had previously been exposed to TNF antagonists and who 
smoked, which are known risk factors for exacerbation and 
manifestation of CD, respectively.32–34 A previous exposure to 
TNF antagonists for primary disease (with inadequate response) 
was observed in 31.5% of the patients with PsA and 28.6% of 
the patients with AS, while 15.1% of the patients with PsO had a 
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Table 1 Selected baseline characteristics of the safety population
Parameter PsO cohort (n=5181) PsA cohort (n=1380) AS cohort (n=794)
Gender
  Female (n, %) 1743 (33.6%) 742 (53.8%) 265 (33.4%)
  Male (n, %) 3438 (66.4%) 638 (46.2%) 529 (66.6%)
Age, years, mean (SD) 45.7 (13.3) 48.8 (12.0) 42.4 (12.3)
Prior exposure (with inadequate response) to TNF antagonists, n (%) NA* 435 (31.5%) 227 (28.6%)
Prior exposure (with inadequate response) to biological therapy, n (%) 784 (15.1%) NA NA
Current smoker at BL, n (%) 1585 (30.6%) 262 (19%) 234 (30%)
Prior azathioprine use, n (%) 7 (0.1%) 15 (1.1%) 1 (0.1%)
*Specific data on prior TNF antagonist exposure is not available for the PSO cohort however 784 (15.1%) of these patients had a previous exposure with inadequate response to 
biologic therapies including TNF antagonists.
AS, ankylosing spondylitis; BL, baseline; CD, Crohn’s disease; PsA, psoriatic arthritis; PsO, psoriasis; UC, ulcerative colitis.
Table 2 EAIRs (95% CI) of IBD over the entire treatment period for patients taking any dose of secukinumab
PsO Studies
n=5181
PsA Studies
n=1380
AS Studies
n=794
Median exposure
(min–max), days
505.0 (1–1825) 1067.5 (8–1827) 981.5 (1–1530)
Total exposure, PY 10 416.9 3866.9 1943.1
Incidence, identified by standard definition (preferred term)
  CD, EAIR per 100 PY
  (95% CI)
0.05 (0.02 to 0.11) 0.08 (0.02 to 0.23) 0.4 (0.2 to 0.8)
  UC, EAIR per 100 PY
  (95% CI)
0.13 (0.07 to 0.23) 0.08 (0.02 to 0.23) 0.2 (0.1 to 0.5)
  IBDU, EAIR per 100 PY (95% CI) 0.01 (0.00 to 0.05) 0.05 (0.01 to 0.19) 0.1 (0.0 to 0.3)
EAIR data are displayed to two decimals where N>1000; if N<1000, then data are displayed to one decimal.
AS, ankylosing spondylitis; CD, Crohn’s disease; EAIR, exposure-adjusted incidence rate; IBD, inflammatory bowel disease; IBDU, IBD-unclassified; PY, patient-years; PsA, psoriatic 
arthritis; PsO, psoriasis; UC, ulcerative colitis.
previous exposure to biological therapies, including TNF antag-
onists. In the PsO, PsA and AS groups, respectively, 30.6%, 19% 
and 30% of patients were current smokers at baseline. Out of the 
5181 patients included in the PsO cohort, a history of either CD, 
UC or IBDU was reported in 15 patients (CD: 5 (0.1%); UC: 10 
(0.19%); IBDU: 0). The corresponding numbers in the 1380 PsA 
and 794 AS patient cohort were 8 patients (CD: 2 (0.14%); UC: 
2 (0.14%); IBDU: 4 (0.29%)) and 25 patients (CD: 5 (0.63%); 
UC: 3 (0.38%); IBDU: 17 (2.14%)), respectively.
Incidence rates of Ibd over the entire treatment period
The exposure adjusted incidence rates (EAIRs, per 100 PY) of 
IBD (CD, UC or IBDU) reported during treatment with any 
secukinumab dose are presented in table 2; the EAIRs of IBD 
events varied across indications from <0.1 to 0.4. There was no 
evidence of a dose-response relationship between secukinumab 
dose (150 mg vs 300 mg) and rates of reported IBD (see online 
supplementary table S3). EAIRs are presented on a by-year basis 
in table 3. The EAIRs for each PT and each indication did not 
increase over time.
Crude incidence rates (n) of IBD during study treatment are 
presented in table 4; here, data are presented as exacerbations of 
IBD (for patients with a previous history of IBD) or new-onset 
IBD (for patients without a prior history of IBD).
Over the entire safety period and across indications, there 
were 41 cases of IBD out of 7355 patients (0.56%) exposed 
across the three reported indications. In the PsO cohort, there 
were 14 cases of UC, 5 cases of CD and 1 case of IBDU, with 
EAIRs of 0.13, 0.05 and 0.01, respectively. Of these 20 cases, 
14 were new-onset. In the PsA cohort, there were three cases 
of UC, three cases of CD and two cases of IBDU (EAIRs 0.08, 
0.08, and 0.05); seven of these represented new-onset cases. In 
the AS cohort, there were four cases of UC, eight cases of CD 
and one case of IBDU (EAIRs 0.2, 0.4 and 0.1); of these, nine 
were new-onset.
The mean age (±SD) of the 41 patients who experienced an 
IBD event with secukinumab treatment was 46.1±14.9 years 
which is generally comparable to the mean age of the PsO 
(45.7±13.3), PsA (48.8±12.0) and AS (42.4±12.3) safety popu-
lations examined in this study (table 1). In addition, approxi-
mately two thirds of patients who experienced an IBD event 
were male (63.4%), which is in line with the greater propor-
tion of male patients in the overall safety population (~60%; 
table 1). Of the total 41 IBD cases observed in the analysis across 
the 3 indications, most (30, 0.41% of the total study population 
of 7355 patients) were new cases of which one patient relapsed 
during the study period. The other 11 (0.15% of the total study 
population) patients had a previous history of either IBD, CD or 
UC at baseline and experienced an exacerbation/relapse during 
the study. Among the patients with a history of, or new-onset 
IBD, 14 were discontinued from treatment; 11 of these were 
patients with new-onset IBD.
reported cases of Ibd during the placebo-controlled 
treatment period (up to 16 weeks)
The reported rates of CD and UC during the placebo-con-
trolled treatment period (from baseline up to 12–16 weeks) are 
presented in table 5. During this short-term period, there was 1 
case of UC and 1 case of CD among 2877 secukinumab-treated 
PsO patients (median exposure 84 days), no cases of UC or CD 
among 703 secukinumab-treated PsA patients (median exposure 
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Table 3 EAIRs (95% CI) of IBD by year for patients taking any dose of secukinumab
PsO PsA AS
CD UC IBDU CD UC IBDU CD UC IBDU
Year 1
N=5181
0.12 (0.04 to 
0.28)
0.17 (0.07 to 
0.34)
0.00 (0.00 to 
0.09)
Year 1
N=1380
0.08
(0.00 to 
0.43)
0.08
(0.00 to 
0.43)
0.08
(0.00 to 
0.43)
Year 1
N=794
0.7 (0.2 to 
1.6)
0.4 (0.1 to 
1.2)
0.1 (0.0 to
0.7)
Year 2
N=3268
0.00 (0.00 to 
0.14)
0.20 (0.06 to 
0.46)
0.00 (0.00 to 
0.14)
Year 2
N=1183
0.00 (0.00 to 
0.34)
0.09
(0.00 to 
0.52)
0.00 (0.00 to 
0.34)
Year 2
N=700
0.5 (0.1 to 
1.3)
0.0 (0.0 to 
0.6)
0.0 (0.0 to 
0.6)
Year 3
N=2246
0.00 (0.00 to 
0.20)
0.05 (0.00 to 
0.30)
0.00 (0.00 to 
0.20)
Year 3
N=948
0.3 (0.0 to 
1.0)
0.1 (0.0 to 
0.8)
0.1 (0.0 to 
0.8)
Year 3
N=557
0.2 (0.0 to 
1.3)
0.2 (0.0 to 
1.3)
0.0 (0.0 to 
0.9)
Year 4
N=1627
0.00 (0.00 to 
0.25)
0.07 (0.00 to 
0.38)
0.07 (0.00 to 
0.38)
Year 4
N=587
0.0 (0.0 to 
0.9)
0.0 (0.0 to 
0.9)
0.0 (0.0 to 
0.9)
Year 4
N=332
0.0 (0.0 to 
3.1)
0.0 (0.0 to 
3.1)
0.0 (0.0 to 
3.1)
Year 5
N=1210
0.00 (0.00 to 
1.22)
0.00 (0.00 to 
1.22)
0.00 (0.00 to 
1.22)
Year 5
N=290
0.0 (0.0 to 
3.1)
0.0 (0.0 to 
3.1)
0.0 (0.0 to 
3.1)
NA
Year 1: Week 0–52; Year 2: Week 52–104; Year 3: Week 104–156; Year 4: Week 156–208; Year 5: Week 208–260.
Data are displayed to two decimals where N>1000; if N<1000, then data are displayed to one decimal.
AS, ankylosing spondylitis; CD, Crohn’s disease; EAIR, exposure adjusted incidence rate; IBD, inflammatory bowel disease; IBDU, IBD-unclassified; NA, not available; PsA, psoriatic 
arthritis; PsO, psoriasis; UC, ulcerative colitis.
Table 4 Incidences of exacerbations/new-onset cases of IBD in patients with/without a history of IBD at baseline, respectively
PsO cohort (n=5181) PsA cohort (n=1380) AS cohort (n=794)
History of Ibd at baseline*
History of CD, n (%)† 5 (0.1%) 2 (0.14%) 5 (0.63%)
  Exacerbation of CD during study treatment, n 2 0 3
History of UC, n (%)† 10 (0.19%) 2 (0.14%) 3 (0.38%)
  Exacerbation of UC during study treatment, n 4 1 1
History of IBDU, n (%)† 0 4 (0.29%) 17 (2.14%)
  Exacerbation of IBDU during study treatment, n 0 0 0
new onset cases of Ibd‡
Total number of new-onset cases of CD, n (%)§ 3 (0.06%) 3 (0.22%) 5 (0.63%)
  Relapses, n 1 0 0
Total number of new-onset cases of UC, n (%)§ 10 (0.19%) 2 (0.14%) 3 (0.38%)
  Relapses, n 0 0 0
Total number of new-onset cases of IBDU, n (%)§ 1 (0.02%) 2 (0.14%) 1 (0.13%)
  Relapses, n 0 0 0
*A history of IBD was physician-assessed based on patient history at baseline.
†Medical history percentages are based on n.
‡New-onset cases of IBD were IBD events occuring in patients with no prior history of IBD at baseline.
§New-onset of AE percentages are based on n.
AS, ankylosing spondylitis; CD, Crohn’s disease; IBD, inflammatory bowel disease; IBDU, IBD-unclassified; PsA, psoriatic arthritis; PsO, psoriasis; UC, ulcerative colitis.
112 days) and 1 case of UC and 2 cases of CD among 394 secuk-
inumab-treated AS patients (median exposure 112 days). During 
this time, 323 patients were treated with etanercept as an active 
comparator (median exposure 84 days). Among these patients, 
there was 1 case of UC. The relative risks of developing CD or 
UC in short-term secukinumab studies are presented in online 
supplementary figure S1. Across the various forest plots, the risk 
for CD and UC did not increase when compared with placebo.
reporting rates of Ibd from postmarketing surveillance
The rate of reported IBD was also assessed as part of periodic 
safety surveillance for secukinumab and is provided in table 6. 
The cumulative, postauthorisation, non-clinical trial exposure to 
secukinumab exceeds 96 000 patient-treatment years covering the 
last five PSUR from December 2014 to June 2017, with the same 
data cut-off date of 25 June 2017. The cumulative rate of reported 
events per 100 PY remained stable at approximately 0.20, varying 
between 0.16 to 0.22 per 100 PY over multiple PSUR cycles.
dISCuSSIOn
In this large secukinumab safety analysis (n=7355; cumulative 
exposure=16 2260.9 PY) across 21 clinical trials, and spanning 
up to 5 years of treatment for PsO and PsA and up to 4 years 
in AS, cases of IBD were uncommon (<1%). There were 41 
(0.56%) observed cases of active IBD reported and of these, 30 
(0.41%) were new-onset cases. Furthermore, of the 48 (0.65%) 
patients with a history of IBD at baseline, 11 (0.15%) patients 
had an exacerbation during study treatment. The EAIR per 100 
PY exposures for CD, UC or IBDU ranged between 0.01 and 
0.13 in PsO, between 0.05 and 0.08 in PsA and between 0.1 and 
0.4 in the AS cohort. In the postmarketing safety surveillance 
analysis (cumulative exposure of >96 000 PY), the cumulative 
reporting rate of IBD remained stable at approximately 0.20 
reported events per 100 PY.
The incidence and prevalence of IBD are greater in patients 
with PsO, PsA and AS compared with the general population (see 
online supplementary table S1).1–6 Environmental risk factors 
associated with bowel inflammation, or relapse of existing IBD, 
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Table 5 Incidence of CD and UC in the short-term placebo-controlled treatment period
PsO studies
(Week 12)
PsA studies
(Week 16)
AS studies
(Week 16)
Any secukinumab 
(n=2877)
Placebo (n=793) Any secukinumab 
(n=703)
Placebo (n=300) Any secukinumab 
(n=394)
Placebo (n=196)
Median exposure (min–
max), days
84 (1–223) 84 (1–127) 112 (8–226) 112 (28–156) 112 (8–195) 112 (1–176)
CD, n (%) 1 (0.03) 0 0 1 (0.3) 2 (0.5) 0
UC, n (%) 1 (0.03) 0 0 1 (0.3) 1 (0.3) 0
AS, ankylosing spondylitis; CD, Crohn’s disease; PsA, psoriatic arthritis; PsO, psoriasis; UC, ulcerative colitis.
Table 6 Reporting rates for IBD in postmarketing experience from the secukinumab periodic safety update report
PSur date
26 December 2014–25 
June 2015
26 June 2015–25 
December 2015
25 December 2015–25 
June 2016
25 June 2016–25 
December 2016
25 December 2016–25 
June 2017
Cumulative rate
Cases (n) 4 12 37 46 93 195
Exposure (PY) 1838 7450 16 871 28 549 41 346 96 054
Reporting rate (per 100 PY) 0.22 0.16 0.22 0.16 0.22 0.20
IBD, inflammatory bowel disease; PSUR, periodic safety update reports; PY, patient-years.
include smoking, infections and high doses of NSAIDs used in AS 
therapy.34–37 Additionally, while TNF antagonist therapy is effec-
tive in treating CD and UC,38 previous failure of a TNF antag-
onist in PsO, PsA and AS populations has also been associated 
with exacerbations and less disease control.32 33 Approximately 
one-third of patients with IBD experience an exacerbation of 
disease within 12 months of withdrawal of TNF antagonist 
therapy.39 Active IBD may develop during TNF antagonist 
therapy for inflammatory rheumatic disease, mostly in patients 
with spondyloarthritis receiving etanercept, at a frequency 
of approximately 0.15%.40 In a study of the Food and Drug 
Administration Adverse Event Reporting System (FAERS), 443 
cases of de novo IBD and 43 cases of flares of existing IBD were 
reported in association with etanercept therapy,41 suggesting that 
IBD should be suspected by the treating physician in patients 
receiving etanercept who develop GI symptoms, particularly 
CD. This has also been observed in a clinical trial where etaner-
cept was found to be an ineffective therapy for active CD.42
In the present study, almost one-third of all patients with PsA 
and AS were previously exposed (with inadequate response) to 
TNF antagonist treatments; previous biological exposure was 
also apparent in the PsO cohort, but rates were lower (15.1%). 
Each cohort also included a sizeable patient population of 
current smokers (~30% in the PsO and AS cohorts and 19% in 
the PsA group). The roles played by current smoking and prior 
TNF antagonist therapies in contributing to IBD in secukinum-
ab-treated patients, however, are unclear at this time.
The EAIR of IBD reported during treatment with any secuki-
numab dose over the entire treatment period varied across indi-
cation from <0.1 to 0.4/100 PY. In the per year analysis, EAIRs 
of IBD ranged from 0.0 to 0.7/100 PY. These IBD rates appear 
to be within the range of expected background IRs (per 100 PY) 
of CD and UC among patients with PsO, PsA and AS, which are 
approximately 0.1 in patients with PsA, 0.3 in PsO and 0.7 in 
AS.5 43 44 In an analysis of 72 phase II–IV adalimumab clinical 
trials, including 23 735 patients representing 36 404.6 PY of 
exposure, rates of IBD events ranged from <0.1 to 0.8/100 PY 
across therapeutic indications.45 It should be noted that there are 
limitations to any direct comparison of IBD rates in adalimumab 
clinical trials with those of therapies not indicated to treat IBD. 
It should also be noted that IBD events were not adjudicated in 
the current secukinumab analysis.
In line with the reported background incidence of IBD, the 
observed EAIR of CD was slightly higher among patients with AS 
(0.4) compared with patients with PsO (0.1) and PsA (0.1) in the 
present study (table 2). Rates of UC were generally comparable 
across indications and ranged from 0.1 to 0.2. Genetic/genomic 
data to further elucidate these findings are not available.
Studies using IL-17 inhibitors for the treatment of PSO, 
PsA and AS have previously reported both exacerbations and 
new-onset cases of IBD.28 46 A small (n=59) phase II proof-of-
concept study found that secukinumab was ineffective in treating 
patients with moderate to severe CD. Disease activity worsened 
in 6/39 (15.4%) patients assigned to active treatment and there 
were more serious infections in the treatment group compared 
with those receiving placebo.28 Conclusions from this study 
are limited by its study design, statistical methods, imbalance 
in baseline characteristics and small sample size. Study patients 
randomised to secukinumab had numerically greater disease 
duration (12.2 years vs 10.3 years), previous bowel surgery 
(48.7% vs 15.0%), previous TNF antagonist therapy exposure 
(17.9% vs 0.0%) and prior antibiotic use (17.9% vs 5.0%) 
compared with placebo-treated patients. Also, patients received 
a higher dose of secukinumab (10 mg/kg) than that approved 
for PsO and PsA (300 mg).28 Nevertheless, further clinical 
development in the general population of patients with CD has 
not been pursued. IBD has also been reported in patients with 
PsO receiving ixekizumab, another IL-17A blocker, in which 
CD and UC cases were uncommon (<1%).30 In another study 
using brodalumab, an IL-17 receptor blocker, a disproportionate 
number of cases of worsening CD was noted in patients with 
active CD and no evidence of clinically meaningful efficacy was 
reported.29 It should be, however, noted that brodalumab acts 
by blocking the IL-17 receptor and, hence, may have a broader 
effect on bowel inflammation when compared with secukinumab 
and ixekizumab, which only target IL-17A. Caution is recom-
mended when prescribing IL-17 inhibitors to patients with active 
IBD in the special warnings section of the summary of product 
characteristics for secukinumab and these patients should be 
followed closely.
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In the current study, the EAIRs for CD, UC and IBDU did not 
appear to increase over time through 5 years of secukinumab 
treatment in patients with PSO and PsA or through 4 years of 
secukinumab treatment in patients with AS. This is consistent with 
previously reported long-term secukinumab data, which demon-
strated that the safety profile of secukinumab remains favourable 
through 5 years of PsO treatment with no increases in yearly AE 
rates.47 Similarly, postmarketing surveillance data from the secuk-
inumab PSUR indicates that the overall reporting rates for IBD, 
including CD and UC, were stable over five PSUR cycles (Dec 
2014–June 2017) and occurred infrequently. Also, in the separate 
short-term placebo-controlled treatment period (12–16 weeks), 
CD and UC occurred infrequently with secukinumab.
Studies from the three licensed indications of secukinumab (PsO, 
PsA and AS) only were included in the present analysis. However, 
additional secukinumab phase III trials have been undertaken 
in patients with rheumatoid arthritis (RA) and phase II trials in 
uveitis.48–51 In three RA studies (n=1430) and in three uveitis 
studies (n=274), there were no reported cases of IBD among 
secukinumab-treated patients. The absence of IBD cases in RA 
clinical trials is particularly important to note as, unlike in patients 
with PsO, PsA and AS, patients with RA are typically not consid-
ered at the same increased risk of IBD.52 Likewise, a considerable 
overlap has been described between genetic risk architectures of 
AS, PsO and CD,53 54 but not between RA and CD.
An interesting point of discussion is whether the aetiology of 
IBD coinciding with PsO, PsA or AS, respectively, is the same as in 
general IBD. IBD is an extremely polygenic disease with a diverse 
range of pathophysiologies that are probably related to the indi-
vidual genetic distortions in the patient.55 Genetic risk architec-
ture in IBD, however, relates to the specific intestinal phenotype.56 
While a surprisingly large overlap has been seen in genetic risk 
factors between populations of patients with an isolated diagnosis 
of IBD (CD in particular) and those with PsO or AS,53 54 very little 
is known about individuals who develop both diseases, who most 
likely represent a specific aetiology and pathophysiology common 
to both diseases. This could explain why IL-17 blockade may not 
be effective in patients with active CD, but does not appear to be 
a risk factor in individuals developing CD as a comorbidity in PsA, 
PsO and AS. This area will represent an important area for future 
research with respect to both specific (genetic) aetiopathology and 
therapeutic behaviour.
Of the 7355 patients with PsO, PsA and AS included in the 
current study, 48 (0.65%) had a previous history of IBDU/CD/UC. 
This baseline rate of IBD incidence does appear to be generally 
lower than rates of IBD previously reported among patients with 
PsO (0.2%–1.6%),57 58 PsA (3.8%),59 and AS (6.6%–8.5%).59 60 
This may be explained by the exclusion of patients with active 
ongoing IBD in the AS studies or patients with active ongoing 
inflammatory diseases other than PsO/PsA that might confound 
the evaluation of therapy in the PsO and PsA studies, respectively. 
The strength of this report is the fact that the analysis is under-
taken in a large patient population pooled from 21 clinical trials 
across multiple indications and is complemented with substantial 
postmarketing surveillance data. The use of exposure-adjusted 
incidence rates also enhances the robustness of the results by 
adjusting for disease duration. Long-term comparative registry 
data are needed to further examine the role of IL-17 inhibition on 
the incidence of IBD.
COnCluSIOn
In this large safety analysis of 7355 patients across 21 clinical trials, 
events of CD, UC and IBDU were uncommon with secukinumab 
treatment. The observed EAIRs for these three disease designations 
did not increase over time with secukinumab treatment.
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Supplementary Figure 1. Relative risks of developing CD or UC in short term secukinumab studies 
 
a) Risk of Crohn’s Disease in PsO Phase III studies 
 
 
b) Risk of Crohn’s Disease in PsA Phase III studies 
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 c) Risk of Crohn’s Disease in AS Phase III studies 
 
 
 
d) Risk of UC in PsO Phase III studies 
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e) Risk of UC in PsA Phase III studies 
 
 
 
f) Risk of UC in AS Phase III studies 
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AIN457, secukinumab; AS, ankylosing spondylitis; CD, Crohn’s disease; CI, confidence interval; CD, Crohn’s disease; PsA, psoriatic 
arthritis; PsO, psoriasis; UC, ulcerative colitis   
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Supplementary Table 1. Approximate increased incidence risk of CD and UC in patients with PsO, PsA, 
and AS compared to the general population  
 
  
Approximate increased incidence compared to the 
general population* 
  Crohn’s Disease Ulcerative Colitis 
PsO  2–4 fold(1-4) 1–2 fold(2-4) 
PsA 2–3 fold(4, 5) 2 fold(4, 5) 
AS 3 fold (IBD)(6) 
aCited studies examined disease rates using different methodologies including incidence rates, relative 
risks, odds ratios and prevalence ratios 
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 Supplementary Table 2. Summary of studies included in the pooled safety analysis of the entire secukinumab treatment period (from 
commencement date up to the cut-off date of June 25, 2017)  
 
Study name Study 
identifier 
Number of 
patients 
included 
Comparator Dose of secukinumab 
Psoriasis studies  
CLEAR (2317) NCT02074982 335 Ustekinumab, 
placebo 
300 mg qw/q4w SC 
GESTURE (2312) NCT01806597 199 Placebo 300, 150 mg qw/q4w SC 
ERASURE (2302) NCT01365455  702 Placebo 300, 150 mg qw/q4w SC 
JUNCTURE (2309) NCT01636687 177 Placebo 300, 150 mg qw/q4w SC 
FIXTURE (2303) NCT01358578 936 Etanercept and 
Placebo 
300, 150 mg qw/q4w SC 
SCULPTURE (2304) NCT01406938 966 N/A 300, 150 mg qw/q4w SC, RAN 
FEATURE (2308) NCT01555125 174 Placebo 300, 150 mg qw/q4w SC 
TRANSFIGURE (2313) NCT01807520 190 Placebo 300, 150 mg qw/q4w SC 
2PRECISE (3301) NCT02008890 214 Placebo 300, 150 mg qw/q4w SC 
CARIMA (ADE02) NCT02559622 150 Placebo 300, 150 mg qw/q4w SC 
PSORITUS (ADE03) NCT02362789 130 Placebo 300 mg qw SC 
GAIN (ADE04) NCT02474069 772 N/A 300 mg q4w SC 
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PRIME (ADE06) NCT02474082 105 Fumaric acid 
esters 
300 mg qw/q4w SC 
JP01 NCT02547714 34 N/a 300 mg q4w SC 
SCALP (AUS01) NCT02267135 97 Placebo 300 mg q4w SC 
Psoriatic arthritis studies 
FUTURE 1 (2306) NCT01392326 587 Placebo 10 mg/kg IV → 150, 75 mg q4w 
SC 
FUTURE 2 (2312) NCT01752634 387 Placebo 300, 150, 75 mg qw/q4w SC 
FUTURE 3 (2318) NCT01989468 406 Placebo 300, 150 mg qw/q4w SC 
Ankylosing spondylitis studies 
MEASURE 1 (2305) NCT01358175  360 Placebo 10 mg/kg IV → 150, 75 mg q4w 
SC 
MEASURE 2 (2310) NCT01649375 211 Placebo 150, 75 mg qw/q4w SC 
MEASURE 3 (2314) NCT02008916 223 Placebo 10 mg/kg IV → 300, 150 mg 
q4w SC 
IV, intravenous; Qw, once a week; Q4w, every 4 weeks; SC, subcutaneous; RAN, retreatment as needed 
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Supplementary Table 3. EAIRs (95% CI) of IBD over the entire treatment period for patients receiving 
secukinumab 150 mg or secukinumab 300 mg 
 
 
PsO Studies PsA Studies AS Studies 
 150 mg 300 mg 150 mg 300 mg 150 mg 300 mg 
Total exposure, PY 3815.5 6601.4 1913.1 940.9 961.8 196.0 
Incidence, identified by standard definition (Preferred Term) 
 150 mg 300 mg 150 mg 300 mg 150 mg 300 mg 
CD, EAIR per 100 PY  
[95% CI] 
0.05 [0.01, 
0.19] 0.05 [0.01, 0.13] 
0.0 [0.0, 
0.2] 0.1 [0.0, 0.6] 
0.2 [0.0, 
0.8] 
0.0 [0.0, 
1.9] 
UC, EAIR per 100 PY  
[95% CI] 
0.16 [0.06, 
0.34] 
0.12 [0.05, 
0.24] 
0.1 [0.0, 
0.3] 0.1 [0.0, 0.6] 
0.2 [0.0, 
0.8] 
0.0 [0.0, 
1.9] 
IBDU, EAIR per 100 PY   
[95% CI] 
0.03 [0.00, 
0.15] 
0.00 [0.00, 
0.06] 
0.0 [0.0, 
0.2] 0.2 [0.0, 0.8] 
0.0 [0.0, 
0.4] 
0.0 [0.0, 
1.9] 
AS, ankylosing spondylitis; CI, confidence interval; CD, Crohn’s disease ; EAIR, exposure-adjusted 
incidence rate; IBD, inflammatory bowel disease; IBDU, IBD-unclassified; PsA, psoriatic arthritis; PsO, 
psoriasis; PY, patient-years; UC, ulcerative colitis    
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